4.8 Article

Lanthanide-Nucleotide Coordination Nanoparticles for STING Activation

Journal

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
Volume 144, Issue 36, Pages 16366-16377

Publisher

AMER CHEMICAL SOC
DOI: 10.1021/jacs.2c03266

Keywords

-

Funding

  1. National Natural Science Foundation of China [82172094]
  2. Funds of Sichuan Province for Distinguished Young Scholars [2021JDJQ0037]
  3. National Research Foundation
  4. Prime Minister's Office of Singapore under its NRF Investigatorship Programme [NRF-NRFI05-2019-0003]

Ask authors/readers for more resources

This study presents the design and synthesis of nanoparticle formulations that can stimulate immune responses and inhibit tumor growth. These nanoparticles, which act as surrogates for STING agonists, show improved bioactivity and immune enhancement compared to traditional agonists.
Activation of the stimulator of interferon genes (STING) is essential for blocking viral infections and eliciting antitumor immune responses. Local injection of synthetic STING agonists, such as 2'3'-cGAMP [cGAMP = cyclic 5'-guanosine monophosphate (cGMP)-adenosine monophosphate (AMP)], is a promising approach to enhance antiviral functions and cancer immunotherapy. However, the application of such agonists has been hindered by complicated synthetic procedures, high doses, and unsatisfactory systemic immune responses. Herein, we report the design and synthesis of a series of 2'3'-cGAMP surrogates in nanoparticle formulations formed by reactions of AMP, GMP, and coordinating lanthanides. These nanoparticles can stimulate the type-I interferon (IFN) response in both mouse macrophages and human monocytes. We further demonstrate that the use of europium-based nanoparticles as STING-targeted adjuvants significantly promotes the maturation of mouse bone-marrow-derived dendritic cells and major histocompatibility complex class I antigen presentation. Dynamic molecular docking analysis revealed that these nanoparticles bind with high affinity to mouse STING and human STING. Compared with soluble ovalbumin (OVA), subcutaneously immunized europium-based nanovaccines exhibit significantly increased production of primary and secondary anti-OVA antibodies (similar to 180-fold) in serum, as well as IL-5 (similar to 28-fold), IFN-gamma (similar to 27-fold), and IFN-alpha/beta (similar to 4-fold) in splenocytes ex vivo. Compared with the 2'3'-cGAMP/OVA formulation, subcutaneous administration of nanovaccines significantly inhibits B16F10-OVA tumor growth and prolongs the survival of tumor-bearing mice in both therapeutic and protective models. Given the rich supramolecular chemistry with lanthanides, this work will enable a readily accessible platform for potent humoral and cellular immunity while opening new avenues for cost-effective, highly efficient therapeutic delivery of STING agonists.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available